New Highs For KPJ Healthcare As Revenue Breaks Records
New Highs For KPJ Healthcare As Revenue Breaks Records
As per the analysts' analysis on the operational front, KPJ saw increased patient visits, with outpatient visits rising by 2% and inpatient visits increasing by 7% year-on-year, bringing the total patient visits to 887,665 in 3Q24. The company's bed occupancy rate also improved by 6 percentage points quarter-on-quarter to 72%, as the number of operational beds rose by 42% to 3,787.KPJ Healthcare Bhd (KPJ) has received positive updates from analysts, with both RHB Investment Bank Bhd (RHB Research) and MIDF Amanah Investment Bank Bhd (MIDF Research) maintaining BUY calls on the company. RHB Research has raised its target price to RM3, offering a 29% upside, while MIDF Research maintained a target price of RM2.54, reflecting a 9% expected return.
KPJ医疗有限公司(KPJ) 收到分析师的积极反馈，RHb投资银行有限公司(RHb Research)和MIDF阿马纳投资银行有限公司(MIDF Research)均对该公司维持买入评级。RHb Research将目标价提高至RM3，提供29%的上涨空间，而MIDF Research维持目标价为RM2.54，预计回报为9%。
KPJ recently reported a strong performance in 3Q24, with a 29% year-on-year (YoY) increase in core earnings to RM86 million, which contributed to a total of RM211 million for the first nine months of 2024, accounting for 74% and 73% of RHB Research and street's full-year estimates, respectively.
KPJ最近报告了2024年第三季度的强劲业绩，核心盈利同比增长29%，达到8600万令吉，2024年前九个月的总营业收入为21100万令吉，分别占RHb Research和市场全年预估的74%和73%。
The company's highest-ever revenue of RM1.003 billion in 3Q24, up 14% from the previous year, was driven by robust patient traffic and an improved patient case mix. As a result, the core profit surged by 29%, and an interim dividend of 1.15 sen per share was declared, up from 0.8 sen in 3Q23.
公司在2024年第三季度创下的营业收入达10.03亿令吉，同比增长14%，这一增长主要得益于患者流量的增加和患者病例组合的改善。因此，核心利润激增29%，并宣布了每股1.15仙的中期股息，较2023年第三季度的0.8仙有所增加。
As per the analysts' analysis on the operational front, KPJ saw increased patient visits, with outpatient visits rising by 2% and inpatient visits increasing by 7% year-on-year, bringing the total patient visits to 887,665 in 3Q24. The company's bed occupancy rate also improved by 6 percentage points quarter-on-quarter to 72%, as the number of operational beds rose by 42% to 3,787.
根据分析师对运营方面的分析，KPJ的患者就诊量增加，其中门诊就诊量同比增长2%，住院就诊量同比增长7%，2024年第三季度总患者就诊量达到887,665人次。公司的床位使用率也较上一季度提高了6个百分点，达到72%，运营床位数量增加了42%，达到3,787张。
MIDF Research's analysis highlighted that KPJ's 9MFY24 revenue increased by 14.5% YoY to RM2.9 billion, with normalised earnings growing by 34.8% to RM247.3 million. The increase in patient visits and higher bed capacity were key contributors to this positive performance. Despite a decline in revenue from other business segments, including the divestment of its Australian operations in early 2024, KPJ's fundamentals remain strong. The Malaysian government's allocation of RM45.3 billion to the Ministry of Health in Budget 2025 is also expected to support the growth of the healthcare sector.
MIDF Research的分析指出，KPJ的2024财政年度前九个月营业收入同比增长14.5%，达到29亿令吉，正常化盈利增长34.8%，达到24730万令吉。患者就诊量的增加和更高的床位容量是这一积极表现的关键因素。尽管其他业务板块的收入有所下降，包括2024年初剥离其澳大利亚业务，KPJ的基本面依然强劲。马来西亚政府在2025年预算中分配给卫生部的453亿令吉也有望支持医疗行业的增长。
Analysts from both RHB Research and MIDF Research are optimistic about KPJ's outlook, noting the company's strategic expansion of its bed capacity and talent acquisition initiatives. While competition in the healthcare sector and cost pressures remain key risks, analysts believed KPJ is well-positioned to maintain its positive trajectory.
来自RHb Research和MIDF Research的分析师对KPJ的前景表示乐观，指出公司在床位容量扩展和人才招聘方面的战略。尽管医疗行业的竞争和成本压力仍是主要风险，但分析师认为KPJ已做好准备，能够维持其积极的发展轨迹。
